Charles Ryhee
Stock Analyst at TD Cowen
(2.44)
# 2,297
Out of 4,784 analysts
25
Total ratings
52.38%
Success rate
0.19%
Average return
Main Sectors:
Stocks Rated by Charles Ryhee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Buy | $73 → $80 | $67.14 | +19.15% | 5 | Nov 25, 2024 | |
| WBA Walgreens Boots Alliance | Maintains: Buy | $16 → $14 | $11.19 | +25.11% | 6 | Oct 22, 2024 | |
| MCK McKesson | Maintains: Buy | $563 → $652 | $668.06 | -2.40% | 4 | May 8, 2024 | |
| CVX Chevron | Maintains: Outperform | $185 → $170 | $166.09 | +2.35% | 3 | Feb 24, 2023 | |
| EVH Evolent Health | Maintains: Outperform | $57 → $59 | $9.60 | +514.58% | 2 | Jan 30, 2023 | |
| CAH Cardinal Health | Maintains: Market Perform | $59 → $72 | $136.44 | -47.23% | 1 | Aug 16, 2022 | |
| OTRK Ontrak | Downgrades: Underperform | $3,150 → $810 | $1.48 | +54,629.73% | 2 | Aug 20, 2021 | |
| TDOC Teladoc Health | Maintains: Outperform | $240 → $188 | $8.09 | +2,223.86% | 1 | Aug 9, 2021 | |
| OSCR Oscar Health | Initiates: Market Perform | $29 | $13.30 | +118.05% | 1 | Mar 29, 2021 |
CVS Health
Nov 25, 2024
Maintains: Buy
Price Target: $73 → $80
Current: $67.14
Upside: +19.15%
Walgreens Boots Alliance
Oct 22, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $11.19
Upside: +25.11%
McKesson
May 8, 2024
Maintains: Buy
Price Target: $563 → $652
Current: $668.06
Upside: -2.40%
Chevron
Feb 24, 2023
Maintains: Outperform
Price Target: $185 → $170
Current: $166.09
Upside: +2.35%
Evolent Health
Jan 30, 2023
Maintains: Outperform
Price Target: $57 → $59
Current: $9.60
Upside: +514.58%
Cardinal Health
Aug 16, 2022
Maintains: Market Perform
Price Target: $59 → $72
Current: $136.44
Upside: -47.23%
Ontrak
Aug 20, 2021
Downgrades: Underperform
Price Target: $3,150 → $810
Current: $1.48
Upside: +54,629.73%
Teladoc Health
Aug 9, 2021
Maintains: Outperform
Price Target: $240 → $188
Current: $8.09
Upside: +2,223.86%
Oscar Health
Mar 29, 2021
Initiates: Market Perform
Price Target: $29
Current: $13.30
Upside: +118.05%